Annual dose of osteoporosis drug better than daily to boost brittle bones’ strengthApril 10th, 2009 - 5:29 pm ICT by ANI
London, Apr 10 (ANI): Osteoporosis drug, if taken once annually, is better at increasing the strength of brittle bones than a daily dose of the same, says a new study.
The researchers, led by Prof David M Reid, from the University of Aberdeen, found that bone density increased faster in patients injected with zoledronic acid-which has been hailed as a breakthrough in treatment of the condition.
But over fifty percent of women stop taking the drugs within a year partly because the medication needs to be taken after fasting for 30 minutes and can cause side effects.
Osteoporosis attacks the density of patients’ bones, making them more brittle and likely to fracture or break.
It occurs mostly in women after menopause or triggered by the using drugs to target other disease.
In the new study, researchers focussed on patients who had developed the condition after taking a group of drugs called glucocorticoids, which is used to treat inflammatory diseases such as rheumatoid arthritis and asthma.
They compared the effect of giving 833 patients either a once-a-year infusion of zelondric acid or the current standard treatment of daily oral drugs.
The results found that the annual treatment increased bone density by an average of 4.1 per cent.
On the other hand, when patients were given one of the standard drugs, in this case risedronate, bone density increased by 2.7 per cent.
The side effects were common, including fever and a deterioration in symptoms from rheumatoid arthritis, but occurred only in the first three days after infusion.
“Guidelines recommend prescription of risedronate or alendronate in many patients given glucocorticoids, who are at increased risk of fracture,” The Telegraph quoted the study as saying.
It concluded: “However, our study has shown that one intravenous infusion of zoledronic acid provides greater increases in bone mineral density and more rapid and substantial decreases in bone turnover than does daily risedronate.”
The researchers called for larger studies to establish whether increasing bone density will cut the rate of fracture.
The study is published in the latest issue of The Lancet. (ANI)
- Drug counters bone-damaging effects of breast cancer medication - Oct 10, 2011
- Modified bone drug kills malaria parasite - Feb 28, 2012
- This drug can reduce breast cancer recurrence - Sep 27, 2011
- Osteoporosis drug may benefit patients with oral cancer - Dec 14, 2010
- Why common drugs can lead to broken bones - Jun 09, 2010
- New research holds promise for development of novel osteoporosis drug - Oct 05, 2010
- Bone drug may help fight breast cancer - Jun 03, 2010
- New drug slows oesteoarthritis progression (Lead) - Mar 23, 2012
- Fracture prone? Blame your genes - Apr 22, 2012
- New drug 'slows' oesteoarthritis progression - Mar 23, 2012
- Keep tab on osteoporosis pain-reliever: Experts (Oct 20 is World Osteoporosis Day) - Oct 19, 2011
- Bone drug may help prevent spread of early lung cancer - Feb 26, 2011
- Thinning of bones linked to heart failure - Feb 03, 2012
- Age of onset of puberty predicts adult osteoporosis risk - Jan 29, 2011
- Osteoporosis, the next big health worry for India (Oct 20 is World Osteoporosis Day) - Oct 20, 2011
Tags: alendronate, bone density, bone mineral density, brittle bones, deterioration, fracture, glucocorticoids, inflammatory diseases, intravenous infusion, menopause, oral drugs, osteoporosis, osteoporosis drug, prof david, rheumatoid arthritis, risedronate, study researchers, substantial decreases, university of aberdeen, zoledronic acid